189 related articles for article (PubMed ID: 27338786)
1. Effect of benazepril, robenacoxib and their combination on glomerular filtration rate in cats.
King JN; Panteri A; Graille M; Seewald W; Friton G; Desevaux C
BMC Vet Res; 2016 Jun; 12(1):124. PubMed ID: 27338786
[TBL] [Abstract][Full Text] [Related]
2. Effect of benazepril and robenacoxib and their combination on glomerular filtration rate in dogs.
Panteri A; Kukk A; Desevaux C; Seewald W; King JN
J Vet Pharmacol Ther; 2017 Jan; 40(1):44-56. PubMed ID: 27302598
[TBL] [Abstract][Full Text] [Related]
3. Effect of Cyclooxygenase(COX)-1 and COX-2 inhibition on furosemide-induced renal responses and isoform immunolocalization in the healthy cat kidney.
Pelligand L; Suemanotham N; King JN; Seewald W; Syme H; Smith K; Lees P; Elliott J
BMC Vet Res; 2015 Dec; 11():296. PubMed ID: 26634699
[TBL] [Abstract][Full Text] [Related]
4. Effects of the angiotensin converting enzyme inhibitor benazepril in cats with induced renal insufficiency.
Brown SA; Brown CA; Jacobs G; Stiles J; Hendi RS; Wilson S
Am J Vet Res; 2001 Mar; 62(3):375-83. PubMed ID: 11277203
[TBL] [Abstract][Full Text] [Related]
5. Aldosterone breakthrough with benazepril in furosemide-activated renin-angiotensin-aldosterone system in normal dogs.
Lantis AC; Ames MK; Atkins CE; DeFrancesco TC; Keene BW; Werre SR
J Vet Pharmacol Ther; 2015 Feb; 38(1):65-73. PubMed ID: 25224804
[TBL] [Abstract][Full Text] [Related]
6. Robenacoxib versus meloxicam for the control of peri-operative pain and inflammation associated with orthopaedic surgery in cats: a randomised clinical trial.
Speranza C; Schmid V; Giraudel JM; Seewald W; King JN
BMC Vet Res; 2015 Mar; 11():79. PubMed ID: 25880535
[TBL] [Abstract][Full Text] [Related]
7. Safety evaluation of the interchangeable use of robenacoxib in commercially-available tablets and solution for injection in cats.
Heit MC; Stallons LJ; Seewald W; Thompson CM; Toutain CE; King SB; Helbig R
BMC Vet Res; 2020 Sep; 16(1):355. PubMed ID: 32988403
[TBL] [Abstract][Full Text] [Related]
8. Safety of oral robenacoxib in the cat.
King JN; Hotz R; Reagan EL; Roth DR; Seewald W; Lees P
J Vet Pharmacol Ther; 2012 Jun; 35(3):290-300. PubMed ID: 21736587
[TBL] [Abstract][Full Text] [Related]
9. Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2.
King JN; Dawson J; Esser RE; Fujimoto R; Kimble EF; Maniara W; Marshall PJ; O'Byrne L; Quadros E; Toutain PL; Lees P
J Vet Pharmacol Ther; 2009 Feb; 32(1):1-17. PubMed ID: 19161451
[TBL] [Abstract][Full Text] [Related]
10. Effect of renal insufficiency on the pharmacokinetics and pharmacodynamics of benazepril in cats.
King JN; Strehlau G; Wernsing J; Brown SA
J Vet Pharmacol Ther; 2002 Oct; 25(5):371-8. PubMed ID: 12423228
[TBL] [Abstract][Full Text] [Related]
11. Effect of tepoxalin on renal function in healthy dogs receiving an angiotensin-converting enzyme inhibitor.
Fusellier M; Desfontis JC; Madec S; Gautier F; Marescaux L; Debailleul M; Gogny M
J Vet Pharmacol Ther; 2005 Dec; 28(6):581-6. PubMed ID: 16343292
[TBL] [Abstract][Full Text] [Related]
12. Effects of route of administration and feeding schedule on pharmacokinetics of robenacoxib in cats.
King JN; Jung M; Maurer MP; Schmid VB; Seewald W; Lees P
Am J Vet Res; 2013 Mar; 74(3):465-72. PubMed ID: 23438125
[TBL] [Abstract][Full Text] [Related]
13. Effect of meloxicam or robenacoxib administration timing on renal function and postoperative analgesia in cats undergoing ovariohysterectomy: A randomized, blinded, controlled clinical trial.
Krekis A; King JN; D'Arcy-Howard D; Stapleton N; Elliott J; Pelligand L
J Vet Pharmacol Ther; 2024 May; 47(3):175-186. PubMed ID: 38235901
[TBL] [Abstract][Full Text] [Related]
14. Robenacoxib in the dog: target species safety in relation to extent and duration of inhibition of COX-1 and COX-2.
King JN; Arnaud JP; Goldenthal EI; Gruet P; Jung M; Seewald W; Lees P
J Vet Pharmacol Ther; 2011 Jun; 34(3):298-311. PubMed ID: 21492194
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology, safety, efficacy and clinical uses of the COX-2 inhibitor robenacoxib.
Lees P; Toutain PL; Elliott J; Giraudel JM; Pelligand L; King JN
J Vet Pharmacol Ther; 2022 Jul; 45(4):325-351. PubMed ID: 35460083
[TBL] [Abstract][Full Text] [Related]
16. Differential pharmacokinetics and pharmacokinetic/pharmacodynamic modelling of robenacoxib and ketoprofen in a feline model of inflammation.
Pelligand L; King JN; Hormazabal V; Toutain PL; Elliott J; Lees P
J Vet Pharmacol Ther; 2014 Aug; 37(4):354-66. PubMed ID: 24628410
[TBL] [Abstract][Full Text] [Related]
17. Safety evaluation of the interchangeable use of robenacoxib (Onsior™) tablets and solution for injection in dogs.
Toutain CE; Heit MC; King SB; Helbig R
BMC Vet Res; 2017 Nov; 13(1):359. PubMed ID: 29179750
[TBL] [Abstract][Full Text] [Related]
18. In vitro and ex vivo inhibition of COX isoforms by robenacoxib in the cat: a comparative study.
Schmid VB; Seewald W; Lees P; King JN
J Vet Pharmacol Ther; 2010 Oct; 33(5):444-52. PubMed ID: 20840388
[TBL] [Abstract][Full Text] [Related]
19. Six-month safety evaluation of robenacoxib tablets (Onsior™) in dogs after daily oral administrations.
Toutain CE; Brossard P; King SB; Helbig R
BMC Vet Res; 2018 Aug; 14(1):242. PubMed ID: 30119677
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic/pharmacodynamic modelling of robenacoxib in a feline tissue cage model of inflammation.
Pelligand L; King JN; Toutain PL; Elliott J; Lees P
J Vet Pharmacol Ther; 2012 Feb; 35(1):19-32. PubMed ID: 21767277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
